# Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma

> **NCT00027911** · PHASE1 · TERMINATED · sponsor: **Columbia University**

## Conditions studied

- Sarcoma

## Interventions

- **BIOLOGICAL:** NY-ESO-1 peptide vaccine
- **BIOLOGICAL:** sargramostim

## Key facts

- **NCT ID:** NCT00027911
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-04
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** — (—)
- **Why stopped:** Departure of PI
- **Last updated:** 2013-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00027911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00027911, "Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00027911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*